Z33.1 Insurance Policy Changes

ICD-10 Z33.1 is officially defined as "Pregnant state, incidental." code Z33.1 is referenced in 9 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z33.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Jan 1, 2027Medium impact
Home Birth by Certified Nurse Midwives 11.01.23
Policy 11.01.23 added CPT codes 59080, 59082 and 59431 in a code edit dated 10/30/26, and the source states that these codes are effective 01/01/2027. Home birth by a certified nurse midwife is considered medically appropriate when the individual is essentially healthy and the midwife holds a current state license, meets the collaborative relationship requirements, and maintains malpractice insurance of no less than $1 million per incident and $3 million for multiple incidents that expressly covers home births. The current effective date is October 22, 2026, and the 10/22/26 annual review left the policy intent unchanged.
Excellus BlueCross BlueShield · Effective Jul 16, 2026High impact
Genetic Testing for Cystic Fibrosis 2.02.17
The July 16, 2026 update made expanded CFTR testing (CPT 81223) medically necessary when standard variant testing is insufficient to establish a diagnosis or assess reproductive risk, and when results will impact clinical or reproductive decision-making. Common-variant CF genetic testing is medically appropriate when results will impact clinical care, the test is performed by a CLIA-certified laboratory, and a listed circumstance applies, such as diagnostic testing for people with symptoms of CF and a negative sweat test, carrier testing for people with a family history of CF, or prenatal testing when both parents have a diagnosis of CF.
Aetna · Identified Oct 5, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2026-08-28)
Aetna considers blood lead testing medically necessary for diagnosis of persons with signs and symptoms of lead poisoning and for pregnant or lactating women who have any listed lead exposure risk factor. Lead screening is covered for persons with occupational lead exposure and, as a preventive service, for children in listed high-risk groups. Measurement of lead in bone, hair, teeth, or urine is considered experimental, investigational, or unproven.
Aetna · Identified Oct 1, 2026Medium impact
Dialysis (CPB 0541, reviewed 2026-08-26)
Aetna's dialysis policy (CPB 0541), last reviewed 08/26/2026, considers hemodialysis or intermittent peritoneal dialysis up to 3 times per week medically necessary for renal failure. More frequent dialysis is considered medically necessary when hyperkalemia, hypophosphatemia, pregnancy, fluid overload, acute pericarditis, congestive heart failure, pulmonary edema or severe catabolic state is refractory to dialysis 3 times per week. Home hemodialysis equipment, supplies and skilled nursing visits are considered medically necessary when prescribed by a physician for members with end stage renal disease, and the equipment is usually rented during the first 30 months of hemodialysis.
Aetna · Identified Aug 18, 2026Medium impact
Obsolete and Unreliable Tests and Procedures (CPB 0438, reviewed 2026-07-16)
Aetna considers a list of tests experimental, investigational, or unproven because CMS has determined they are obsolete or unreliable, they have been replaced by more advanced procedures, or professional specialty societies do not recommend them, and the list includes the lupus erythematosus cell test, cardiointegram, and several serum and skin tests. Aetna also considers a set of obsolete procedures experimental, investigational, or unproven, including colectomy to treat epilepsy, mammary artery ligation for coronary artery disease, optic nerve decompression for non-arteritic anterior ischemic optic neuropathy, radiation therapy for acne, Ali Krogius procedure for patellofemoral instability, and visceral osteopathy. Each listed test or procedure has CPT, HCPCS, or ICD-10 codes that are not covered for the indications the policy names.
Aetna · Identified Aug 18, 2026Medium impact
Maternal Biomarker Screening for Fetal Conditions (CPB 0464, reviewed 2026-07-17)
Aetna covers cell-free DNA fetal RhD genotyping when the pregnancy may be at risk for alloimmunization, paternal antigen typing is unavailable or heterozygous, and amniocentesis is declined or contraindicated. Multiple serum marker testing is covered for pregnant women who have been adequately counseled and want information on their risk of having a Down syndrome fetus, and NIPT for fetal aneuploidy (trisomy 13, 18 and 21, and sex chromosome aneuploidy) is covered for all pregnant women with the listed tests. Performing more than one screening test, such as NIPT with multiple marker screening, is considered not medically necessary, and cell-free DNA screening for microdeletion syndromes, rare autosomal trisomies, single-gene and multi-gene screening, and other listed approaches are considered experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Lead Testing (CPB 0553, reviewed 2025-11-26)
Aetna considers blood lead testing medically necessary to diagnose people with signs or symptoms of lead poisoning, and for pregnant or lactating women who have any of the listed lead exposure risk factors. Routine blood lead testing for average-risk pregnant women without risk factors is not considered medically necessary. Lead screening is covered for persons with occupational lead exposure, which OSHA mandates, and as preventive care for children in high-risk groups under CDC, USPSTF, AAP and AAN guidance, while measuring lead in bone, hair, teeth or urine is considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)
Aetna considers several vaginitis tests medically necessary for women with symptoms of vaginitis, including nucleic acid amplification or DNA probe assays for trichomonas, Candida and Gardnerella for members with dysuria or symptoms of vaginitis, sialidase activity testing such as the BVBlue test, and pH and amine testing of vaginal fluid. Screening for Trichomonas vaginalis is considered medically necessary for women with risk factors such as HIV-positive status, new or multiple partners, a history of sexually transmitted diseases, exchange of sex for payment, injection drug use, or high-prevalence settings such as STD clinics and correctional facilities. A Pap smear for the diagnosis of Candida vulvo-vaginitis, routine screening for Candida and Gardnerella in asymptomatic women, the uBiome SmartJane screen, and the 27-organism vaginal pathogen panel from Bridge Diagnostics are considered experimental, investigational, or unproven because their effectiveness has not been established.
Presbyterian Health Plan · Identified Jul 31, 2026Medium impact
2026 July Network Connection
CPT 90785 (interactive complexity) may be billed only as an add-on code that accompanies an eligible primary psychiatric service, and only when its specific criteria and requirements are met. Medical records must clearly support CPT 90785 by describing specific communication challenges, challenges affecting clinical interaction, the interactive methods used, and why standard communication approaches were insufficient, and claims submitted without adequate documentation may be subject to audit or review with payment adjusted if billing requirements are not met. Nail pathogen panel claims should be supported by clear clinical indication and medical necessity, prior testing and treatment history, a valid signed provider order specifying test type, and accurate diagnosis coding, and the Presbyterian Program Integrity Department performs random claims validation audits.

Watch Z33.1

Get one email when a payer policy names Z33.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z33.1?

There are 9 tracked policy changes affecting code Z33.1, including updates from Excellus BlueCross BlueShield, Aetna, Presbyterian Health Plan. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z33.1?

Payers that have issued tracked updates for code Z33.1 include: Excellus BlueCross BlueShield, Aetna, Presbyterian Health Plan.

How do I get notified when code Z33.1 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z33.1. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z33.1?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Home Birth by Certified Nurse Midwives 11.01.23

Genetic Testing for Cystic Fibrosis 2.02.17

Lead Testing (CPB 0553, reviewed 2026-08-28)

Dialysis (CPB 0541, reviewed 2026-08-26)

Obsolete and Unreliable Tests and Procedures (CPB 0438, reviewed 2026-07-16)

Maternal Biomarker Screening for Fetal Conditions (CPB 0464, reviewed 2026-07-17)

Lead Testing (CPB 0553, reviewed 2025-11-26)

Diagnosis of Vaginitis (CPB 0643, reviewed 2025-12-15)

2026 July Network Connection

What insurance policy changes affect code Z33.1?

Which payers have updated policy for code Z33.1?

How do I get notified when code Z33.1 policy changes?

Why do payers change policies for code Z33.1?